Publicaciones en colaboración con investigadores/as de Hospital General Universitario de Valencia (60)

2024

  1. KRAS-mutant non-small cell lung cancer (NSCLC) therapy based on tepotinib and omeprazole combination

    Cell Communication and Signaling, Vol. 22, Núm. 1

  2. Soluble galectin-3 as a microenvironment-relevant immunoregulator with prognostic and predictive value in lung adenocarcinoma

    Molecular Oncology, Vol. 18, Núm. 1, pp. 190-215

2023

  1. A Sonic Hedgehog Pathway Score to Predict the Outcome of Resected Non-Small Cell Lung Cancer Patients

    Annals of Surgical Oncology, Vol. 30, Núm. 2, pp. 1225-1235

  2. ASO Visual Abstract: A Sonic Hedgehog Pathway Score to Predict the Outcome of Resected Non-small Cell Lung Cancer Patients

    Annals of surgical oncology, Vol. 30, Núm. 2, pp. 1238-1239

  3. Circulating Immune Proteins: Improving the Diagnosis and Clinical Outcome in Advanced Non-Small Cell Lung Cancer

    International Journal of Molecular Sciences, Vol. 24, Núm. 24

  4. Clinical and technical insights of tumour mutational burden in non-small cell lung cancer

    Critical Reviews in Oncology/Hematology, Vol. 182

2022

  1. Analysis of Exosomal Cargo Provides Accurate Clinical, Histologic and Mutational Information in Non-Small Cell Lung Cancer

    Cancers, Vol. 14, Núm. 13

  2. Programmed Death-Ligand 1 (PD-L1) as Immunotherapy Biomarker in Breast Cancer

    Cancers, Vol. 14, Núm. 2

2021

  1. 3D printing novel in vitro cancer cell culture model systems for lung cancer stem cell study

    Materials Science and Engineering C, Vol. 122

  2. Analysis of the gut microbiota: An emerging source of biomarkers for immune checkpoint blockade therapy in non-small cell lung cancer

    Cancers, Vol. 13, Núm. 11

  3. Cancer epigenetic biomarkers in liquid biopsy for high incidence malignancies

    Cancers, Vol. 13, Núm. 12

  4. Characterization of circulating t cell receptor repertoire provides information about clinical outcome after pd-1 blockade in advanced non-small cell lung cancer patients

    Cancers, Vol. 13, Núm. 12

  5. Differentially methylated genes in proliferative verrucous leukoplakia reveal potential malignant biomarkers for oral squamous cell carcinoma

    Oral Oncology, Vol. 116

  6. Exosomal microRNAs in non-small cell lung cancer

    Translational Cancer Research, Vol. 10, Núm. 6, pp. 3128-3139

  7. NGS-based liquid biopsy profiling identifies mechanisms of resistance to ALK inhibitors: a step toward personalized NSCLC treatment

    Molecular Oncology, Vol. 15, Núm. 9, pp. 2363-2376

  8. R-score: A new parameter to assess the quality of variants’ calls assessed by ngs using liquid biopsies

    Biology, Vol. 10, Núm. 10

  9. The status of egfr modulates the effect of mirna-200c on zeb1 expression and cell migration in glioblastoma cells

    International Journal of Molecular Sciences, Vol. 22, Núm. 1, pp. 1-18

  10. Update on systemic treatment in early triple negative breast cancer

    Therapeutic Advances in Medical Oncology, Vol. 13

  11. dPCR application in liquid biopsies: divide and conquer

    Expert Review of Molecular Diagnostics, Vol. 21, Núm. 1, pp. 3-15

2020

  1. A profile on cobas® EGFR Mutation Test v2 as companion diagnostic for first-line treatment of patients with non-small cell lung cancer

    Expert Review of Molecular Diagnostics, Vol. 20, Núm. 6, pp. 575-582